Регулирование заразительных осложнений в создании химической антигенной приемной клетки (CAR-T)

1. Introduction

Chimeric antigen receptor T-cell (CAR T-cell) is an adoptive immunotherapy utilizing genetically modified autologous T-cells that recognize tumor antigens. This therapy changed the paradigm in the management of refractory or relapsed non-Hodgkin’s lymphoma (NHL), acute lymphoblastic leukemia (ALL), and relapsed refractory multiple myeloma (RRMM). Despite the success, CAR T-cell therapy presents with unique potential toxicity profile, specifically cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndromes (ICANS). While these toxicities prevail in the first few weeks post-infusion, infection is emerging as the most important cause of non-relapse mortality (NRM).

Presently approved CAR T-cell therapies target CD-19, and B cell maturation antigen (BCMA) found on B cells and plasma cells, respectively. CD-19-directed therapies for relapsed and refractory NHL and ALL include axicabtagene autoleucel (axi-cel), tisagenlecleucel (tisacel), brexucabtagene autoleucel (brexu-cel) and lisocabtagene maraleucel (liso-cel). 1–7 Since 2021, BCMA-directed CAR-T have been approved for RRMM, including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). 8,9 Additional approvals in additional indications and earlier lines of care are anticipated. 1,2 There is also continued interest in the development of novel CARs, including allogeneic CARs, and in expanding the indications to solid tumors and autoimmune diseases.

Given the morbidity and NRM associated with infections, we review their incidence and patterns and the approach to monitoring and prevention of serious infectious complications of CAR-T therapy. This review describes the general considerations and principles for CD19 and BCMA directed therapies. These principles are applicable in adults and children for the FDA approved indications and may also be useful for investigational CAR-T for NHL and RRMM.

2. The emergence of infections as a significant concern

2.1. Incidence

The incidence of infection varies for CD19 and BCMA CAR-T recipients. Single center reports demonstrate that the incidence of any grade infections can be over 50% in CD19 CAR-T. 10 The cumulative incidence of infection with CD19 CAR-T up to 1 year can be 63.3% for axi-cel and tisa-cel, with 23% being severe and most being bacterial. 11 A single-center retrospective study on axi-cel recipients identified that, in the first month, 36.5% patients developed infection, of which, in 12.9%, was severe. 12 On univariate analysis, CRS, ICANS, corticosteroids, and tocilizumab use was associated with an increased risk of infection. 12 Beyond 30 days, Meir et al. reported the incidence of any grade infections/febrile neutropenia in pivotal trials for CD19 CAR-T therapies ranging from 32-43% (any grade) (3-13% grade ≥ 3) for NHL and ALL. 13 A systematic review of all infections across MM, NHL, and ALL reported a 17% incidence of severe (Grade ≥3) infections, including both early and late infections. 14 Meanwhile, for BCMA-directed CAR-T, any grade infection was 69% for ide-cel and 58% for cilta-cel (22-20% grade ≥3 respectively). 13

2.2. Mortality due to infectious complications

Infection is emerging as an important preventable cause of NRM. Relapse rates after CAR-T therapy are around 40-60% and disease relapse accounts for the majority of all-cause of deaths in CAR-T recipients. Death from infectious complications accounts for 1% of all-cause deaths and remains the driver of NRM in CAR-T recipients. 10,12,14,15 When specifically evaluating the causes of NRM, we find that infection is the main driver. A recent investigation on mantle cell lymphoma patients who received brexu-cel reported that NRM was 6% at 180 days, mostly driven by infections. 16 A recent French DESCAR-T registry study reviewing patients with R/R NHL who received CD19 CAR-T therapy found an overall rate of NRM of 5% in the treated population, most of these occurring beyond Day 30, with infections being responsible for the majority (56%) of NRM events. 17 Another global report on axi-cel and tisa-cel recipients found that NRM was 5.4% and infections accounted for the highest mortality rate amongst these, at 2.42%. 18 As for BCMA-directed therapies, the KarMMa trial reported infection-related mortality in 2% of all ide-cel recipients. 8 The NRM with BCMA therapies in the late period is yet to be described, but is expected to be similar or higher than for CD19 CAR-T, given the increased incidence of infections in BCMA CAR-T recipients. 19 With the continued use of CAR T-cell therapy as an established treatment in hematological malignancies, and the ongoing early phase studies in solid tumors, it is imperative that we continue to evaluate and strive to understand the infection risk associated with this therapy and develop management strategies with the aim of decreasing NRM.

2.3. Phases and patterns of Infections

Infections can be broadly divided into periods that are “pre-infusion” ,“early” infections, and “late” infections ( Figure 1 ). The phases are based on the dominant component of the immune state which is compromised and timing from day of cell infusion. 10

Pre-Infusion Phase: This is from time of lymphodepletion (LD) to cell infusion ( Day -7 to Day 0). Patients may have impaired immunity with prior therapies and active disease. Infections during this period are likely attributable to therapy prior to LD (e.g., bridging) and exposures that occurred in proximity to initiation of LD therapy (e.g. respiratory viral infections).

Early Phase : This period is from the day of infusion to Day 30, dominated by cytopenia. Due to effects of LD, neutropenia is commonly seen early on during this phase. Lymphopenia and B cell aplasia also develop during this period. CD4+ T cell counts were shown to decrease from baseline and to remain low at a median CD4 of 155cells/mL at 1 year post axi-cel. 20 CD16/56 NK cells, CD4 and CD8 T cells were all depleted after LD. CD16/56 cells recover typically by Day 28 (14-87 days), and CD 8+ cells by Day 21, while CD4+ cells remain suppressed with inverted CD4/CD8 ratio inversion for up to a year. 21 While observed with both CD19 and BCMA CAR-T, earlier severe neutropenia, lymphopenia and hypogammaglobulinemia can be seen in BCMA CAR-T compared to CD19 CAR-T recipients. 22

The presence of high-grade CRS, surge of inflammatory cytokines, and use of immune suppression for management of CRS and neurotoxicity, including tocilizumab and steroids, may impact duration of neutropenia. Infections in the early period are mostly bacterial (68%) and are severe. Moderate viral infections are more prevalent later. 15

Late Phase: The late phase is defined as the period beyond the initial 30 days post-infusion. This phase is dominated by prolonged neutropenia, dysregulation of humoral and adaptive immunity with lymphopenia, hypogammaglobinemia, and B cell aplasia.

Prolonged neutropenia increases the ongoing risk of bacterial infections. Hematological toxicity can have a cumulative 1-year incidence of 58% post-CD19 CAR-T, and may show a biphasic course, with initial neutrophil recovery followed by a “second dip”. 23 A single center retrospective study of 85 axi-cel patients attempted to characterize the immune reconstitution and infection risk for patients, demonstrating that grade ≥ 3 neutropenia was prevalent in 30% patients at Day 30 and in 7% at 1 year. 20 Another study demonstrated that, at 2 years, 11% of patients had grade ≥ 3 cytopenia. 24 BCMA CAR-T recipients had a higher incidence of prolonged neutropenia, with 40% grade ≥3 cytopenia prevalent at Day 90. 13 Hypogammaglobulinemia onset is typical after 2 weeks post infusion, and occurred in 35%, 27% and 46% of patients between day 15-30, 31-60 and 61-90, respectively. 21,25 CD19+ B cells have been reported to remain low, resulting in deficiency of the humoral immune system, until a median of 79 days in a study on CD19 CAR-T in ALL patients. 21 As for BCMA CAR-T recipients, the CAR-T targets BCMA expressing cells, including mature B lymphocytes and plasma cells, which are a vital arm of the humoral immune system. 26 Moderate viral infections are more prevalent during this period. 15 Reynold et al. reported that late were as common as early infections in NHL population, while the latter was twofold higher than late infections in ALL. 14 The patterns of infections differ in these phases and are visualized in Figure 1 .

2.4. Patterns of infection by organism

2.4.1. Bacterial infections: These are common, especially early post infusion. The known real-world incidence and severity is mostly based on retrospective data. In the early CAR-T period, bacterial infections account for 40-50% infections, typically occurring within the first 2 weeks. 11,12,20 Another study found that up to 90% of bacterial infections occurred in the first 4 weeks with the highest risk with neutropenia. 27 This includes blood stream infections, central venous catheter-related infections and can be organ specific such as gastrointestinal or respiratory. 11,12,20 In addition, urinary tract infections were also reported. 28 Common bacteria include gram positive organisms, gram negative Enterobacteriaceae , and Clostridium . 11,20 In a study of ALL children and adolescent CAR-T recipients, the incidence of bacteremia was 39%, with risk factors being IgG ≤ 400 mg/dL, severe CRS and lymphodepleting chemotherapy (LD) other than fludarabine and cyclophosphamide, and prior allogeneic hematopoietic stem cell transplant (alloHCT). 29

Also, most patients receive empiric broad spectrum antibiotics for neutropenic fever, which can possibly relate to noninfectious causes, such as CRS in the early post infusion period. Such patients are at risk of dysregulation of gut microbiome. A study by Hu et al showed that second- generation CAR-T severe CRS can alter the gut microbiota. 30 The “microbiome” and efficacy of CAR-T is being studied. 31

2.4.2. Viral infections: One analysis found that 50% of infections in CAR-T recipients were viral, with 80% being respiratory infections. 32 These are relatively more common after Day 30 for CD19-directed CAR-T. During the first 30 days, they are the second most common after bacterial infections, although they may be higher for RRMM even in the early phase. 28,33

2.4.2.1. Non respiratory viral infections: These include Herpes simplex virus (HSV), Varicella-zoster virus (VZV), cytomegalovirus (CMV) and Human herpesvirus type 6 (HHV6). 24 Delayed reactivation of HSV and VZV can be seen around 6-12 months after infusion. 11 CMV reactivation is seen in 1-2%, although the exact incidence is not known as testing is not frequently done. 34

2.4.2.2. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection: Amongst respiratory viral infections, there has been heightened focus on SARS-CoV-2, which was declared a global pandemic in 2020. CAR-T recipients are one of the highest risk groups for SARS-CoV-2 infection and at highest risk of prolonged viral shedding. 35 Mortality was around 30-40 % in HCT recipients during the pandemic. 36,37 A single center report of HCT and CAR-T recipients in 2021 demonstrated that 28% of those with coronavirus disease-19 (COVID-19) infection, had severe disease. 38 There was prolonged viral shedding for a median of 7.7 weeks . 38 In another European study of 57 patients, admission for COVID-19 was 80%, with 43% requiring oxygen support and 39% intensive care unit admission. 37 Over the years, several SARS-CoV-2 variants have emerged, with varying risks of morbidity, including Alpha, Beta, Gamma, Delta and Omicron, with multiple subvariants and sub-branches. 39 The outcomes vary by variant, and are worse in those patients with lymphopenia, higher ferritin and who develop COVID-19 close to infusion. 38,40,41 Therapies such as remdesivir, nirmatrelvir/ritonavir and immunizations have contributed to improved outcomes in recent years. 42,43 Although the World Health Organization (WHO) declared that the pandemic no longer constitutes a ‘public health emergency of international concern’ on May 5, 2023, COVID-19 is still present in localized small outbreaks and is still considered to be a risk for morbidity and mortality in CAR-T recipients. 44

2.4.3. Invasive Fungal infections and Pneumocystic jirovecii pneumonia (PJP) : Invasive fungal infections , including fungal infections occur in 1-5% in CAR-T recipients. 33,45,46 The risk factors include prolonged neutropenia the use of high dose or long duration of corticosteroids, and severe CRS. 45,46 This usually occurs within the first month post infusion. 25 PJP can occur beyond the first month, but overall is rare, likely due to widespread prophylaxis. ( Figure 1 )

2.5. Factors influencing Post CAR-T Infection Risk

Infections occur due to an interplay of several factors, such as immunosuppression with LD and bridging therapies, cytopenia and immune dysregulation with CAR-T, CRS and ICANS. 13

Factors are summarized in Figure 2 and include:

2.5.1.Patient-Related Factors: Patient ethnicity, health condition, presence of comorbidities, functional status and chronic infections (e.g. immunodeficiency at infusion, Human immunodeficiency virus (HIV) and hepatitis infections). 47 Jacobson, et al reported that patients receiving axi-cel had broader comorbidities, including 4% with requiring ongoing microbial treatment. 48 Impaired performance status and history of infections within 30 days before CAR-T was a risk factor for severe bacterial infection. 11 Post cellular therapy, especially HCT, in patients with COVID-19 infection, age > 50 years was a prognostic factor. 36 A report by Dayagi et al on 88 patients with relapsed/ refractory leukemia/lymphoma who received CD19 CAR-T demonstrated that children had less severe infections than adults. 49 Older age is associated with an impairment of the immune system, due to a decrease in immunological diversity of naïve T cells and an increasing number of senescent T cells, which leads to a higher susceptibility to disease and infection. 50

2.5.2. Disease-Related Factors: The risk of any grade infection post CAR-T is highest in RRMM, compared to NHL and ALL patients, with 57% all-grade infections. 14 RRMM patients also had the highest risk of severe infections including bacterial and viral infections. 14 IgG subtype and high-grade CRS were risk factors. 22 Disease or therapy-related cytopenia and lymphopenia at baseline increase the risk of prolonged cytopenia and its associated infections. 24 Other factors include baseline cytopenia secondary to disease, duration of prior therapies, immunosuppressive therapies previously used (e. g. infusion of CD20 monoclonal antibodies, which is associated with B cell aplasia), prior CAR-T cell therapy and prior alloHCT. 51 Hypogammaglobulinemia and associated humoral immune dysfunction are additional “on-target, off-tumor” effects related to profound plasma cell aplasia that can last >200 days after cell infusion. 25 Moreover, lack of response was associated with higher risk of infections. 49 Maintenance therapies and subsequent therapies, such as BCMA bispecific antibodies for myeloma or CD20 bispecific antibodies for lymphoma also must be taken into consideration when evaluating immune reconstitution and preventative strategies. Further investigation and consensus on management is ongoing.

2.5.3. LD regimen: LD is employed to allow effective T cell expansion. The most used regimens include fludarabine and cyclophosphamide (Flu/Cy) or bendamustine. The risk of infection is considered to be higher with Flu/Cy compared to bendamustine. 52 However, data are conflicting, and another study in ALL patients showed that the risk of infection was highest in non-Flu/Cy LD. 29 Enhanced LD with higher Flu/Cy doses may also increase the risk of infections. 53

2.5.4.CAR-T characteristics: B cell aplasia is an off-tumor on-target effect of both CD19 and BCMA-directed CAR-T therapies. Novel targets such as mucin-1 targeting with p-MUC-1 or other solid tumor targets that are not expressed on immune cells, may not cause profound immunosuppression. Meanwhile, the impact of BCMA–directed CAR T cells on humoral immune dysfunction may be even more profound than that caused by CD19-directed T cells, because of BCMA expression on long-lived bone marrow plasma cells that produce pathogen–specific antibody responses. 22,54 The infection risk may vary by co-stimulatory signaling domains (4-1BB versus CD28), which are associated with varying risks of severe CRS. 12 However, there is no head-to-head comparison between products.

2.5.5.CRS and ICANS and associated therapies: CRS and immune dysregulation may lead to tissue damage and endothelial dysfunction, thereby increasing the risk of infections. 13 Prolonged steroid use with high grade ICANS may predispose CAR-T recipients to developing CMV reactivation and fungal infections. Moreover, febrile neutropenia treated with broad spectrum antibiotics can potentially interfere with the gut microbiome and alter immune reconstitution.

3. Infection Prevention

3.1. Pre-infusion considerations to reduce risk of infection

3.1.1. Screening prior to leukapheresis and cell infusion

Screening for infections constitutes a pivotal element in the pre-CAR-T-cell therapy risk evaluation. 55 Active bacteremia , fungal infections and viremia should be controlled prior to collection. 55 All patients should undergo serologic testing for HIV, Hepatitis B virus (HBV), and Hepatitis C virus (HCV) within 30 days of leukapheresis. 55–57 Additionally, serologic screening for HSV and VZV proved valuable in guiding the use of antiviral prophylaxis, specifically with valacyclovir/acyclovir. 56 This prophylactic measure is recommended throughout the 6 to 12 months post-CAR-T-cell therapy, with potential consideration for future VZV vaccination. Furthermore, CMV serologic screening may be contemplated before CAR-T-cell therapy. 56 Assessment of latent infections for individual patients, including Mycobacterium tuberculosis , human T-cell lymphotropic virus type 1, Strongyloides stercoralis , Toxoplasma gondii and Treponema pallidum can be considered based on their medical history and epidemiologic risk factors. 56,58 At cell infusion, screening for COVID-19 is recommended to detect asymptomatic infection. Asymptomatic patients testing positive for COVID-19 by qPCR may proceed to CAR-T manufacture, but this is done at risk and at the physician’s discretion. 55

3.1.2. Active infection at infusion

To minimize the risk of morbidity, patients should not have an active infection at the time of cell infusion. 55 In those with respiratory symptoms, who should undergo workup to test for the source of respiratory viral illness, a delay should be considered, especially for patients with COVID-19, respiratory syncytial virus, parainfluenza virus 1 to 4, influenza virus A or B, metapneumovirus and adenovirus. 58 In case of COVID-19 positivity, the delay should ideally be of 14 days, allowing for resolution of symptoms. However, if early infusion is considered, retesting in 5-7 days and proceeding, if testing is negative and the patient is asymptomatic, may be reasonable and warranted, if the potential benefit outweighs the risk. 59 When possible, cell infusion should be postponed until count recovery from bridging or prior therapy is achieved, to avoid prolonged cytopenia. While factors such as timing of CAR-T, LD chemotherapy and bridging may not be controlled, it is imperative to be aware of these factors and educate patients and monitor for infections.

3.2. Prophylactic strategies

These are mostly adopted from consensus statements and practice guidelines 58 and summarized in Table 1 :

3.2.1 . Antibacterial prophylaxis: This should be implemented during periods of severe neutropenia, with an absolute neutrophil count (ANC) < 500/mm 3 . Fluoroquinolone prophylaxis is routinely used. 25,58

3.2.2. Antiviral prophylaxis: This is typically prophylactic acyclovir 400mg-800 PO twice a day or valacyclovir 500mg PO twice a day starting at LD and continuing for at least 6 months post infusion. 58 No prophylaxis for herpesviruses other than HSV and VZV is recommended.

3.2.3. Antifungal prophylaxis: Antifungal prophylaxis with fluconazole 200mg PO daily is recommended while the ANC is below 500/mm 3 . 16 Based on the 2018 American Society of Clinical Oncology (ASCO) and Infectious Diseases Society of America (IDSA) guidelines, mold prophylaxis is recommended if the population-level risk of aspergillosis is ≥6%. 60 While institutional guidelines may vary, mold prophylaxis should, in general, be offered to patients who have prolonged neutropenia (> 3 weeks) , receive high doses of corticosteroids (≥ dexamethasone 10mg per day, for more than 3 days or methylprednisolone ≥ 1gm IV), use of > 1 dose of tocilizumab or second line agents such as anakinra, as well as those with prior mold infections. 46,58 In these patients, mold prophylaxis for 1 month after completion of immunosuppressive therapy is recommended. 58

3.2.3. PJP Prophylaxis : Trimethoprim/sulfamethoxazole is recommended to be initiated around 1 month post CAR-T, if blood counts allow. Otherwise, other less myelosuppressive options such as inhaled pentamidine, dapsone or atovaquone, should be instituted, typically until the CD4+ count is over 200/uL. 11,61

3.2.4. SARS-CoV-2 prophylaxis: Pre-exposure prophylaxis with neutralizing monoclonal antibodies (tixagevimab/cilgavimab) was recommended in 2021 but is not effective against the new dominant variants and, thus, is no longer recommended presently. 44,62,63

3.3. Immunizations

Vaccination strategies in patients post-CAR T-cell therapy are crucial to ensure the continued protection of these individuals against infectious diseases while considering the unique immunological landscape shaped by CAR T-cell treatment. Immunogenicity and safety of post CAR T-cell vaccinations are unknown, and patients may have a lower response. Extended absence of B-cell function, the depletion of memory B cells, and ensuing hypogammaglobulinemia could compromise the effectiveness of humoral protection against a range of infections, including those preventable through vaccination. 64 A thoughtful and tailored approach to vaccination becomes imperative to strike a balance between promoting immune response and preventing potential complications. 58 Furthermore, a personalized and comprehensive assessment of each patient’s vaccination status and history is crucial for guiding vaccination decisions. This includes evaluating prior immunizations, assessing the need for booster shots, and considering any pre-existing immunity.

One key aspect of vaccination strategies in post-CAR T-cell therapy patients involves careful timing. Vaccination should be deferred until the recovery of immune function, which may take several weeks to months after CAR T-cell infusion. This delay allows the immune system to regain its strength, reducing the risk of adverse events and ensuring the effectiveness of the vaccines. Additionally, prioritizing vaccinations against vaccine-preventable diseases, such as influenza, pneumococcus, and other common pathogens, is essential. Moreover, the choice of vaccines may need to be adjusted based on the specific nature of the patient’s underlying malignancy and the potential impact of the CAR T-cell therapy on the immune response.

3.3.1.Respiratory viral vaccinations: The recommendations are summarized in Table 2 .

The influenza vaccine should be given annually prior to the expected influenza season, and 2 weeks prior to LD chemotherapy. The introduction of mRNA vaccines has resulted in favorable response rates for SARS-CoV-2, even with vaccination as early as 3 months post-HCT. 66 This development provides a compelling basis for contemplating their use in recipients of CAR-T-cell therapy. The RSV vaccination was recently approved in 2023 for all adults ≥ 60 years old. 67 Based on our expert opinion, the RSV vaccination can be offered post Day 100.

3.3.2. Inactivated vaccinations: Consensus guidelines recommend the administration of killed or inactivated vaccines at least three months after CAR-T therapy. 44,64 Before vaccination, patients should exhibit immune reconstitution, characterized by CD4+ counts exceeding 0.2×10 9 /L and CD19 or CD20+ B cell counts surpassing 0.2×10 9 /L. It is crucial that patients have not undergone concurrent immunosuppressive treatments, including cytotoxic chemotherapy, systemic corticosteroids, T-cell-depleting or anti-lymphocyte agents, or intravenous immunoglobulin (IVIg) within the preceding two months. 64

3.3.3. Live Vaccinations: Divergent guidelines advise maintaining a distinction in the administration of live vaccines until at least one-year post-CAR-T therapy, contingent upon the demonstration of immune reconstitution. Some expert groups go further to contraindicate live vaccines within the initial eight months following intravenous IVIg replacement. 65 Notably, centers such as the Fred Hutchinson Cancer Center recommend a delay in both live and non-live adjuvant vaccines, until a minimum of five months have elapsed since the last IVIg replacement. 68 Ultimately, a well-considered vaccination strategy is integral to promoting long-term immune health in individuals who have undergone CAR T-cell therapy, reducing the risk of infectious complications and supporting their journey towards sustained remission.

The recommendations for vaccinations after CD19 and BCMA CAR-T, based on the European Society for Blood and Marrow Transplantation ( EBMT), the Joint Accreditation Committee of ISCT and EBMT (JACIE), and the European Hematology Association ( EHA) consensus are shown in Table 3 and Figure 3 . 65 It is important to note that most of these strategies are largely based on expert opinion, extrapolated from autologous transplant protocols. 25,55

3.4. Monitoring and Supportive Care

The management of infections is largely based on expert opinion and extrapolation from transplant protocols. There are no recommended surveillance strategies beyond neutropenic fever management for bacterial infections.

3.4.1. Respiratory Viral Infection Monitoring : For respiratory infection, it is recommended to check a respiratory viral panel only if symptomatic or exposed. There is no routine serological testing recommended, but this would be considered in targeted settings. 58

3.4.2. CMV monitoring: In high- risk patients, those with receiving significant immunosuppressive treatment for management of CRS and ICANS, weekly CMV monitoring for up to 1 month after discontinuation of therapy is recommended ( Table 4 ). 16

3.5. Treatment of Active Infection

Prompt evaluation and management are crucial, particularly for neutropenic patients in the early post-infusion phase. The treatment of infections in patients post CAR T-cell therapy requires a nuanced and vigilant approach, due to the altered immune landscape resulting from this advanced form of cancer treatment. This should include a multidisciplinary team involving infectious disease specialists, hematologists and other healthcare providers, to ensure comprehensive and timely management of potential infections. Prompt identification and targeted treatment of infections are paramount, given the heightened susceptibility of these patients to opportunistic pathogens. Antimicrobial therapy in post-CAR T-cell therapy patients often involves a judicious selection of antibiotics, antifungals or antivirals, based on the pathogens and the patient’s clinical presentation. The choice of antimicrobials may need to be tailored to the individual’s immunization history, local epidemiology, and the potential for drug interactions with ongoing CAR T-cell-related medications. Additionally, close monitoring for signs and symptoms of infection plays a crucial role in early detection and intervention.

The most important strategy to prevent infection-related deaths, especially beyond the early phase, is to educate referring physicians, patients and caregivers about the morbidity and mortality associated with infectious complications. Instructions on preventative measures such as social distancing, hand washing, immunizations and adherence to prophylaxis are crucial. Furthermore, the education of patients, caregivers, and their local physicians about the immune dysregulation with CAR-T, the need for prompt evaluation of respiratory symptoms, fever or other symptoms is critically important. Recognizing that infections are the main cause of NRM and can occur not only in the immediate post-infusion period but also in the later phase, highlights the necessity for a sustained focus on its prevention. Building an infrastructure beyond 30 days, where immunocompromised patients, such as CAR-T recipients, may be able to bypass the emergency department, where long wait times are expected in a space shared with other patients who may have respiratory viruses, may help reduce their exposure to other infections. Given the risk of opportunistic infections in this population, it is imperative that there be a mechanism for direct written and oral communication between the authorized treatment center (ATC) physicians and referral physicians, as well as availability of the ATC team 24/7 for referral team guidance.

3.6. Supportive Care

Supportive strategies play a pivotal role in managing infections in post-CAR T-cell therapy patients ( Table 4 ). Enhancing the patient’s immune system and managing cytopenia can contribute significantly to reducing the risk of serious infections.

3.6.1: Neutropenia: Evaluation of the etiology of prolonged neutropenia is important. Supportive care such as granulocyte-colony stimulating factor (GCSF) may be considered to boost neutrophil counts and enhance the body’s ability to fight infections. 69,73 The thrombopoietin-receptor (TPO) agonist eltrombopag, is also used for prolonged neutropenia, given retrospective evidence of trilineage hematopoietic improvement in the post- CAR-T setting. 28,70,74 CD34+ stem cell boost can also shorten the time to neutrophil recovery. 71

3.6.2. Hypogammaglobenemia: There is a consensus that IgG levels should be monitored before CAR-T-cell therapy infusion and monthly, for at least three months afterwards. 56,57,65 The benefits of universal prophylaxis with IVIg replacement therapy (IGRT) in the context of asymptomatic hypogammaglobulinemia remain unclear. Most of the data on IGRT are extrapolated from patients who receive CD20 monoclonal antibody and alloHCT recipients. 10,75 Criteria that might be particularly relevant for prompt initiation of IGRT include the presence of serious or recurrent bacterial infections when the total serum IgG level is below 400 mg/dL or per institutional protocol. 72 Notably, recipients of BCMA CAR-T-cell therapy exhibit more profound humoral deficits, suggesting a potentially higher benefit from a more liberal use of IGRT. However, to identify patients who would derive the most benefit, as well as to determine the optimal timing, schedule, duration, and modality of IGRT, prospective controlled trials are essential. 75

4. Future Directions and Research

Understanding the implications for the future of CAR-T therapy and patient outcomes is vital in shaping effective infection management strategies.

Further research is needed to better understand immune reconstitution and to develop strategies to minimize or manage prolonged cytopenias. There is an unmet need to identify modifiable baseline risk factors, define neutropenic fever in the context of cytokine release syndrome, determine the benefit of anti-mold prophylaxis, and establish evidence-based approaches to antifungal prophylaxis and diagnosing the risk of life-threatening infections using cytokine patterns. Additionally, more research is warranted to understand the factors contributing to recurrent viral infections, the role of different LD regimens and intensities in defining the patterns of infection, and to develop novel targets and constructs with lower risk of adverse toxicities. Finally, educational material and standard transition of care guidelines for referring oncologists, with an outline on monitoring and surveillance for infections is important to identify and treat infections promptly.

5. Conclusions

In conclusion, the key findings underscore the critical role of prophylactic and preventative strategies, early recognition, and treatment of infection since this is the primary driver of NRM in CAR-T recipients. Prophylactic and preventative strategies for all patients are imperative to mitigate the risk of serious infections. Furthermore, the importance of supportive strategies for immune reconstitution and effective cytopenia management is emerging as a pivotal aspect of patient care, potentially contributing to a reduction in infection-related complications. The time-sensitive nature of prompt evaluation and management, particularly in the early post-infusion period for neutropenic patients, is a crucial element in enhancing patient outcomes. The broader implications for the future of CAR-T therapy and patient well-being extend beyond the initial four weeks, highlighting the need for ongoing vigilance and a sustained focus on infection prevention, even after patients have returned to the community. Improved communication with the ATC beyond the early phase will be important to guide infection monitoring and treatment. This comprehensive understanding of infection dynamics in CAR-T recipients serves as a foundation for refining therapeutic approaches and optimizing patient care to enhance the overall success of CAR-T therapy.

Author contributions

Conceptualization: Nausheen Ahmed (Equal), Olalekan Oluwole (Equal), Zahra Mahmoudjafari (Equal), Nahid Suleman (Equal), Joseph P McGuirk (Equal). Writing – original draft: Nausheen Ahmed (Equal), Zahra Mahmoudjafari (Equal). Writing – review & editing: Nausheen Ahmed (Equal), Olalekan Oluwole (Equal), Zahra Mahmoudjafari (Equal), Nahid Suleman (Equal), Joseph P McGuirk (Equal).

Competing Interests

NA: Consultancy: Kite/Gilead; Advisory Board: Bristol-Myers Squibb.

OO: Consultancy: Pfizer, Kite, Gilead, AbbVie, Janssen, TGR therapeutics, Bioheng, ADC, Novartis, Allogene, Nektar, Caribou.

ZM: Advisory board participation: KITE, BMS, Genentech, Janssen, Pfizer

JPM: Consultant for: Kite, Allovir, Novartis, Nektar, Bristol Myers Squib, Envision,

Sana, Legend Biotech, CRISPER, Autolus

NS reports no conflict of interest

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial The Lancet Kamdar Manali Solomon Scott R Arnason Jon Johnston Patrick B Glass Bertram Bachanova Veronika Ibrahimi Sami Mielke Stephan Mutsaers Pim Hernandez-Ilizaliturri Francisco Izutsu Koji Morschhauser Franck Lunning Matthew Maloney David G Crotta Alessandro Montheard Sandrine Previtali Alessandro Stepan Lara Ogasawara Ken Mack Timothy Abramson Jeremy S Elsevier BV 6 2022 399 10343 2294 2308 0140-6736 10.1016/s0140-6736(22)00662-6 10.1016/s0140-6736(22)00662-6 35717989

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma New England Journal of Medicine Locke Frederick L. Miklos David B. Jacobson Caron A. Perales Miguel-Angel Kersten Marie-José Oluwole Olalekan O. Ghobadi Armin Rapoport Aaron P. McGuirk Joseph Pagel John M. Muñoz Javier Farooq Umar van Meerten Tom Reagan Patrick M. Sureda Anna Flinn Ian W. Vandenberghe Peter Song Kevin W. Dickinson Michael Minnema Monique C. Riedell Peter A. Leslie Lori A. Chaganti Sridhar Yang Yin Filosto Simone Shah Jina Schupp Marco To Christina Cheng Paul Gordon Leo I. Westin Jason R. Massachusetts Medical Society 17 2 2022 386 7 640 654 0028-4793 10.1056/nejmoa2116133 10.1056/nejmoa2116133 34891224

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma New England Journal of Medicine Schuster Stephen J. Bishop Michael R. Tam Constantine S. Waller Edmund K. Borchmann Peter McGuirk Joseph P. Jäger Ulrich Jaglowski Samantha Andreadis Charalambos Westin Jason R. Fleury Isabelle Bachanova Veronika Foley S. Ronan Ho P. Joy Mielke Stephan Magenau John M. Holte Harald Pantano Serafino Pacaud Lida B. Awasthi Rakesh Chu Jufen Anak Özlem Salles Gilles Maziarz Richard T. Massachusetts Medical Society 3 1 2019 380 1 45 56 0028-4793 10.1056/nejmoa1804980 10.1056/nejmoa1804980 30501490

KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study The Lancet Shah Bijal D Ghobadi Armin Oluwole Olalekan O Logan Aaron C Boissel Nicolas Cassaday Ryan D Leguay Thibaut Bishop Michael R Topp Max S Tzachanis Dimitrios O'Dwyer Kristen M Arellano Martha L Lin Yi Baer Maria R Schiller Gary J Park Jae H Subklewe Marion Abedi Mehrdad Minnema Monique C Wierda William G DeAngelo Daniel J Stiff Patrick Jeyakumar Deepa Feng Chaoling Dong Jinghui Shen Tong Milletti Francesca Rossi John M Vezan Remus Masouleh Behzad Kharabi Houot Roch Elsevier BV 8 2021 398 10299 491 502 0140-6736 10.1016/s0140-6736(21)01222-8 10.1016/s0140-6736(21)01222-8 PMC11613962 34097852

Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium Journal of Clinical Oncology Wang Yucai Jain Preetesh Locke Frederick L. Maurer Matthew J. Frank Matthew J. Munoz Javier L. Dahiya Saurabh Beitinjaneh Amer M. Jacobs Miriam T. Mcguirk Joseph P. Vose Julie M. Goy Andre Andreadis Charalambos Hill Brian T. Dorritie Kathleen A. Oluwole Olalekan O. Deol Abhinav Paludo Jonas Shah Bijal Wang Trent Banerjee Rahul Miklos David B. Rapoport Aaron P. Lekakis Lazaros Ghobadi Armin Neelapu Sattva S. Lin Yi Wang Michael L. Jain Michael D. American Society of Clinical Oncology (ASCO) 10 5 2023 41 14 2594 2606 0732-183X 10.1200/jco.22.01797 10.1200/jco.22.01797 36753699 PMC10489553

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia New England Journal of Medicine Maude Shannon L. Laetsch Theodore W. Buechner Jochen Rives Susana Boyer Michael Bittencourt Henrique Bader Peter Verneris Michael R. Stefanski Heather E. Myers Gary D. Qayed Muna De Moerloose Barbara Hiramatsu Hidefumi Schlis Krysta Davis Kara L. Martin Paul L. Nemecek Eneida R. Yanik Gregory A. Peters Christina Baruchel Andre Boissel Nicolas Mechinaud Francoise Balduzzi Adriana Krueger Joerg June Carl H. Levine Bruce L. Wood Patricia Taran Tetiana Leung Mimi Mueller Karen T. Zhang Yiyun Sen Kapildeb Lebwohl David Pulsipher Michael A. Grupp Stephan A. Massachusetts Medical Society 2 2018 378 5 439 448 0028-4793 10.1056/nejmoa1709866 10.1056/nejmoa1709866 29385370 PMC5996391

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial The Lancet Oncology Jacobson Caron A Chavez Julio C Sehgal Alison R William Basem M Munoz Javier Salles Gilles Munshi Pashna N Casulo Carla Maloney David G de Vos Sven Reshef Ran Leslie Lori A Yakoub-Agha Ibrahim Oluwole Olalekan O Fung Henry Chi Hang Rosenblatt Joseph Rossi John M Goyal Lovely Plaks Vicki Yang Yin Vezan Remus Avanzi Mauro P Neelapu Sattva S Elsevier BV 1 2022 23 1 91 103 1470-2045 10.1016/s1470-2045(21)00591-x 10.1016/s1470-2045(21)00591-x 34895487

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma New England Journal of Medicine Munshi Nikhil C. Anderson Larry D., Jr. Shah Nina Madduri Deepu Berdeja Jesús Lonial Sagar Raje Noopur Lin Yi Siegel David Oriol Albert Moreau Philippe Yakoub-Agha Ibrahim Delforge Michel Cavo Michele Einsele Hermann Goldschmidt Hartmut Weisel Katja Rambaldi Alessandro Reece Donna Petrocca Fabio Massaro Monica Connarn Jamie N. Kaiser Shari Patel Payal Huang Liping Campbell Timothy B. Hege Kristen San-Miguel Jesús Massachusetts Medical Society 25 2 2021 384 8 705 716 0028-4793 10.1056/nejmoa2024850 10.1056/nejmoa2024850 33626253

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study The Lancet Berdeja Jesus G Madduri Deepu Usmani Saad Z Jakubowiak Andrzej Agha Mounzer Cohen Adam D Stewart A Keith Hari Parameswaran Htut Myo Lesokhin Alexander Deol Abhinav Munshi Nikhil C O'Donnell Elizabeth Avigan David Singh Indrajeet Zudaire Enrique Yeh Tzu-Min Allred Alicia J Olyslager Yunsi Banerjee Arnob Jackson Carolyn C Goldberg Jenna D Schecter Jordan M Deraedt William Zhuang Sen Hong Infante Jeffrey Geng Dong Wu Xiaoling Carrasco-Alfonso Marlene J Akram Muhammad Hossain Farah Rizvi Syed Fan Frank Lin Yi Martin Thomas Jagannath Sundar Elsevier BV 7 2021 398 10297 314 324 0140-6736 10.1016/s0140-6736(21)00933-8 10.1016/s0140-6736(21)00933-8 34175021

Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy Bone Marrow Transplantation Wudhikarn Kitsada Perales Miguel-Angel Springer Science and Business Media LLC 15 7 2022 57 10 1477 1488 0268-3369 10.1038/s41409-022-01756-w 10.1038/s41409-022-01756-w 35840746 PMC9285870

Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma Blood Cancer Journal Wudhikarn Kitsada Palomba M. Lia Pennisi Martina Garcia-Recio Marta Flynn Jessica R. Devlin Sean M. Afuye Aishat Silverberg Mari Lynne Maloy Molly A. Shah Gunjan L. Scordo Michael Dahi Parastoo B. Sauter Craig S. Batlevi Connie L. Santomasso Bianca D. Mead Elena Seo Susan K. Perales Miguel-Angel Springer Science and Business Media LLC 5 8 2020 10 8 79 2044-5385 10.1038/s41408-020-00346-7 10.1038/s41408-020-00346-7 32759935 PMC7405315

Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells Clin Infect Dis Park Jae H Romero F Andres Taur Ying Sadelain Michel Brentjens Renier J Hohl Tobias M Seo Susan K Oxford University Press (OUP) 22 2 2018 67 4 533 540 1058-4838 10.1093/cid/ciy152 10.1093/cid/ciy152 29481659 PMC6070095

State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses Transplantation and Cellular Therapy Meir Juliet Abid Muhammad Abbas Abid Muhammad Bilal Elsevier BV 12 2021 27 12 973 987 2666-6367 10.1016/j.jtct.2021.09.016 10.1016/j.jtct.2021.09.016 34587552 PMC8473073

Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis Critical Reviews in Oncology/Hematology Reynolds Gemma K. Sim Beatrice Spelman Tim Thomas Ashmitha Longhitano Anthony Anderson Mary Ann Thursky Karin Slavin Monica Teh Benjamin W. Elsevier BV 12 2023 192 104134 1040-8428 10.1016/j.critrevonc.2023.104134 10.1016/j.critrevonc.2023.104134 37739146

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma Blood Adv Logue Jennifer M. Peres Lauren C. Hashmi Hamza Colin-Leitzinger Christelle M. Shrewsbury Alexandria M. Hosoya Hitomi Gonzalez Rebecca M. Copponex Christina Kottra Krista H. Hovanky Vanna Sahaf Bita Patil Sunita Lazaryan Aleksandr Jain Michael D. Baluch Aliyah Klinkova Olga V. Bejanyan Nelli Faramand Rawan G. Elmariah Hany Khimani Farhad Davila Marco L. Mishra Asmita Blue Brandon J. Grajales-Cruz Ariel F. Castaneda Puglianini Omar A. Liu Hien D. Nishihori Taiga Freeman Ciara L. Brayer Jason B. Shain Kenneth H. Baz Rachid C. Locke Frederick L. Alsina Melissa Sidana Surbhi Hansen Doris K. American Society of Hematology 14 12 2022 6 24 6109 6119 2473-9529 10.1182/bloodadvances.2022008320 10.1182/bloodadvances.2022008320 35939783 PMC9768247

Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment. Journal of Clinical Oncology Kambhampati Swetha Ahmed Nausheen Hamadani Mehdi Grover Natalie Sophia Shadman Mazyar Locke Frederick L. Gerson James M. Frank Matthew Joshua Budde Lihua Elizabeth Wang Michael Hu Zhen-Huan Nunes Ana Dalton David Kloos Ioana Lee Daniel Xu Hairong Pasquini Marcelo C. Herrera Alex Francisco American Society of Clinical Oncology (ASCO) 1 6 2023 41 16_suppl 7507 7507 0732-183X 10.1200/jco.2023.41.16_suppl.7507 10.1200/jco.2023.41.16_suppl.7507

[DESCAR-T, a nationwide registry for patient treated by CAR-T Cells in France] Bulletin du Cancer Broussais Florence Bay Jacques Olivier Boissel Nicolas Baruchel André Arnulf Bertrand Morschhauser Franck Robin Marie Guepin Gabrielle Roth Moreau Philippe Gandemer Virginie Manier Salomon Leguay Thibaut Nguyen Quoc Stéphanie Schwartzmann Alexia Houot Roch Le Gouill Steven Elsevier BV 10 2021 108 10s S143 S154 0007-4551 10.1016/j.bulcan.2021.07.002 10.1016/j.bulcan.2021.07.002 34920797

A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy Aging Cai Changjing Tang Diya Han Ying Shen Edward Ahmed Omar Abdihamid Guo Cao Shen Hong Zeng Shan Impact Journals, LLC 24 9 2020 12 18 18741 18753 1945-4589 10.18632/aging.104058 10.18632/aging.104058 32973124 PMC7585129

Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: A systematic scoping review and narrative synthesis Clinical Microbiology and Infection Reynolds Gemma Sim Beatrice Anderson Mary Ann Spelman Tim Teh Benjamin W. Slavin Monica A. Thursky Karin A. Elsevier BV 10 2023 29 10 1280 1288 1198-743X 10.1016/j.cmi.2023.05.011 10.1016/j.cmi.2023.05.011 37201866

Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma Haematologica Logue Jennifer M. Zucchetti Elisa Bachmeier Christina A. Krivenko Gabriel S. Larson Victoria Ninh Daniel Grillo Giovanni Cao Biwei Kim Jongphil Chavez Julio C. Baluch Aliyah Ferrata Storti Foundation (Haematologica) 2021 106 4 978 986 1592-8721 10.3324/haematol.2019.238634 10.3324/haematol.2019.238634 32327504 PMC8017820

Kinetics of immune reconstitution after anti-CD19 chimeric antigen receptor T cell therapy in relapsed or refractory acute lymphoblastic leukemia patients International Journal of Laboratory Hematology Wang Ying Li Hujun Song Xuguang Qi Kunming Cheng Hai Cao Jiang Shi Ming Yan Zhiling Jing Guangjun Pan Bin Sang Wei Wang Xiangmin Zhao Kai Chen Chong Chen Wei Zheng Junnian Li Zhenyu Xu Kailin Wiley 2021 43 2 250 258 1751-5521 10.1111/ijlh.13375 10.1111/ijlh.13375 33112046

Pathogen-Specific Humoral Immunity and Infections in B Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Recipients with Multiple Myeloma Transplantation and Cellular Therapy Josyula Srirama Pont Margot J. Dasgupta Sayan Song Xiaoling Thomas Sushma Pepper Gregory Keane-Candib Jacob Stevens-Ayers Terry L. Ochs Hans D. Boeckh Michael J. Riddell Stanley R. Cowan Andrew J. Krantz Elizabeth M. Green Damian J. Hill Joshua A. Elsevier BV 6 2022 28 6 304.e1 304.e9 2666-6367 10.1016/j.jtct.2022.03.005 10.1016/j.jtct.2022.03.005 35288345 PMC9197988

Antibodies to vaccine-preventable infections after CAR-T-cell therapy for B-cell malignancies JCI insight Walti Carla S. Krantz Elizabeth M. Maalouf Joyce Boonyaratanakornkit Jim Keane-Candib Jacob Joncas-Schronce Laurel Stevens-Ayers Terry Dasgupta Sayan Taylor Justin J. Hirayama Alexandre V. Bar Merav Gardner Rebecca A. Cowan Andrew J. Green Damian J. Boeckh Michael J. Maloney David G. Turtle Cameron J. Hill Joshua A. American Society for Clinical Investigation 29 4 2021 6 11 2379-3708 10.1172/jci.insight.146743 10.1172/jci.insight.146743 33914708 PMC8262349

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma Haematologica Strati Paolo Varma Ankur Adkins Sherry Nastoupil Loretta J. Westin Jason Hagemeister Fredrick B. Fowler Nathan H. Lee Hun J. Ferrata Storti Foundation (Haematologica) 30 7 2020 106 10 2667 2672 1592-8721 10.3324/haematol.2020.254045 10.3324/haematol.2020.254045 32732355 PMC8485681

Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy Blood Hill Joshua A. Li Daniel Hay Kevin A. Green Margaret L. Cherian Sindhu Chen Xueyan Riddell Stanley R. Maloney David G. Boeckh Michael Turtle Cameron J. American Society of Hematology 4 1 2018 131 1 121 130 0006-4971 10.1182/blood-2017-07-793760 10.1182/blood-2017-07-793760 29038338 PMC5755046

BCMA is essential for the survival of long-lived bone marrow plasma cells J Exp Med O'Connor Brian P. Raman Vanitha S. Erickson Loren D. Cook W. James Weaver Lehn K. Ahonen Cory Lin Ling-Li Mantchev George T. Bram Richard J. Noelle Randolph J. Rockefeller University Press 5 1 2004 199 1 91 98 1540-9538 10.1084/jem.20031330 10.1084/jem.20031330 14707116 PMC1887725

Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells Biology of Blood and Marrow Transplantation Cordeiro Ana Bezerra Evandro D. Hirayama Alexandre V. Hill Joshua A. Wu Qian V. Voutsinas Jenna Sorror Mohamed L. Turtle Cameron J. Maloney David G. Bar Merav Elsevier BV 1 2020 26 1 26 33 1083-8791 10.1016/j.bbmt.2019.08.003 10.1016/j.bbmt.2019.08.003 31419568 PMC6953906

Respiratory infections predominate after day 100 following B-cell maturation antigen–directed CAR T-cell therapy Blood Adv Little Jessica S. Tandon Megha Hong Joseph Seungpyo Nadeem Omar Sperling Adam S. Raje Noopur Munshi Nikhil Frigault Matthew Barmettler Sara Hammond Sarah P. American Society of Hematology 15 9 2023 7 18 5485 5495 2473-9529 10.1182/bloodadvances.2023010524 10.1182/bloodadvances.2023010524 37486599 PMC10514400

Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults Open Forum Infect Dis Vora Surabhi B Waghmare Alpana Englund Janet A Qu Pingping Gardner Rebecca A Hill Joshua A Oxford University Press (OUP) 9 4 2020 7 5 ofaa121 2328-8957 10.1093/ofid/ofaa121 10.1093/ofid/ofaa121 32432149 PMC7221263

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies Nature Communications Hu Yongxian Li Jingjing Ni Fang Yang Zhongli Gui Xiaohua Bao Zhiwei Zhao Houli Wei Guoqing Wang Yiyun Zhang Mingming Hong Ruimin Wang Linqin Wu Wenjun Mohty Mohamad Nagler Arnon Chang Alex H. van den Brink Marcel R. M. Li Ming D. Huang He Springer Science and Business Media LLC 9 9 2022 13 1 5313 2041-1723 10.1038/s41467-022-32960-3 10.1038/s41467-022-32960-3 36085303 PMC9461447

CAR-T Cell Therapy and the Gut Microbiota Cancers Asokan Sahana Cullin Nyssa Stein-Thoeringer Christoph K. Elinav Eran MDPI AG 28 1 2023 15 3 794 2072-6694 10.3390/cancers15030794 10.3390/cancers15030794 36765752 PMC9913364

578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy Open Forum Infectious Diseases Tran Nikki Eschenauer Gregory Scappaticci Gianni Frame David Miceli Marisa H Patel Twisha S Oxford University Press (OUP) 1 10 2020 7 Supplement_1 S354 S354 2328-8957 10.1093/ofid/ofaa439.772 10.1093/ofid/ofaa439.772

Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy Blood Adv Kambhampati Swetha Sheng Ying Huang Chiung-Yu Bylsma Sophia Lo Mimi Kennedy Vanessa Natsuhara Kelsey Martin Thomas Wolf Jeffrey Shah Nina Wong Sandy W. American Society of Hematology 29 3 2022 6 7 2045 2054 2473-9529 10.1182/bloodadvances.2020004079 10.1182/bloodadvances.2020004079 34543400 PMC9006279

Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma Cancers Korell Felix Schubert Maria-Luisa Sauer Tim Schmitt Anita Derigs Patrick Weber Tim Frederik Schnitzler Paul Müller-Tidow Carsten Dreger Peter Schmitt Michael MDPI AG 2 4 2021 13 7 1684 2072-6694 10.3390/cancers13071684 10.3390/cancers13071684 33918340 PMC8038233

Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study Clin Infect Dis Hensley Matthew K Bain William G Jacobs Jana Nambulli Sham Parikh Urvi Cillo Anthony Staines Brittany Heaps Amy Sobolewski Michele D Rennick Linda J Macatangay Bernard J C Klamar-Blain Cynthia Kitsios Georgios D Methé Barbara Somasundaram Ashwin Bruno Tullia C Cardello Carly Shan Feng Workman Creg Ray Prabir Ray Anuradha Lee Janet Sethi Rahil Schwarzmann William E Ladinsky Mark S Bjorkman Pamela J Vignali Dario A Duprex W Paul Agha Mounzer E Mellors John W McCormick Kevin D Morris Alison Haidar Ghady Oxford University Press (OUP) 28 1 2021 73 3 e815 e821 1058-4838 10.1093/cid/ciab072 10.1093/cid/ciab072 33507235 PMC7929077

Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study The Lancet Haematology Sharma Akshay Bhatt Neel S St Martin Andrew Abid Muhammad Bilal Bloomquist Jenni Chemaly Roy F Dandoy Christopher Gauthier Jordan Gowda Lohith Perales Miguel-Angel Seropian Stuart Shaw Bronwen E Tuschl Eileen E Zeidan Amer M Riches Marcie L Shah Gunjan L Elsevier BV 3 2021 8 3 e185 e193 2352-3026 10.1016/s2352-3026(20)30429-4 10.1016/s2352-3026(20)30429-4 33482113 PMC7816949

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group Leukemia Spanjaart Anne Mea Ljungman Per de La Camara Rafael Tridello Gloria Ortiz-Maldonado Valentín Urbano-Ispizua Alvaro Barba Pere Kwon Mi Caballero Dolores Sesques Pierre Bachy Emmanuel Di Blasi Roberta Thieblemont Catherine Calkoen Friso Mutsaers Pim Maertens Johan Giannoni Livia Nicholson Emma Collin Matthew Vaz Carlos Pinho Metafuni Elisabetta Martinez-Lopez Joaquin Dignan Fiona L. Ribera Josep-Maria Nagler Arnon Folber Frantisek Sanderson Robin Bloor Adrian Ciceri Fabio Knelange Nina Ayuk Francis Kroger Nicolaus Kersten Marie José Mielke Stephan Springer Science and Business Media LLC 8 11 2021 35 12 3585 3588 0887-6924 10.1038/s41375-021-01466-0 10.1038/s41375-021-01466-0 34750508 PMC8573311

Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients Transplantation and Cellular Therapy Mushtaq Muhammad Umair Shahzad Moazzam Chaudhary Sibgha Gull Luder Mary Ahmed Nausheen Abdelhakim Haitham Bansal Rajat Balusu Ramesh DeJarnette Shaun Divine Clint Kribs Robert Shune Leyla Singh Anurag K. Ganguly Siddhartha Abhyankar Sunil H. McGuirk Joseph P. Elsevier BV 9 2021 27 9 796.e1 796.e7 2666-6367 10.1016/j.jtct.2021.07.005 10.1016/j.jtct.2021.07.005 34256172 PMC8272625

Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era Experimental Hematology & Oncology Zhang Tingting Tian Weiwei Wei Shuang Lu Xinyi An Jing He Shaolong Zhao Jie Gao Zhilin Li Li Lian Ke Zhou Qiang Zhang Huilai Wang Liang Su Liping Kang Huicong Niu Ting Zhao Ailin Pan Jing Cai Qingqing Xu Zhenshu Chen Wenming Jing Hongmei Li Peng Zhao Wanhong Cao Yang Mi Jianqing Chen Tao Chen Yuan Zou Ping Lukacs-Kornek Veronika Kurts Christian Li Jian Liu Xiansheng Mei Qi Zhang Yicheng Wei Jia Springer Science and Business Media LLC 27 7 2023 12 1 66 2162-3619 10.1186/s40164-023-00426-x 10.1186/s40164-023-00426-x 37501090 PMC10375673

COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP Blood Adv Busca Alessandro Salmanton-García Jon Corradini Paolo Marchesi Francesco Cabirta Alba Di Blasi Roberta Dulery Remy Lamure Sylvain Farina Francesca Weinbergerová Barbora Batinić Josip Nordlander Anna López-García Alberto Drgoňa Ľuboš Espigado-Tocino Ildefonso Falces-Romero Iker García-Sanz Ramón García-Vidal Carolina Guidetti Anna Khanna Nina Kulasekararaj Austin Maertens Johan Hoenigl Martin Klimko Nikolai Koehler Philipp Pagliuca Antonio Passamonti Francesco Cornely Oliver A. Pagano Livio American Society of Hematology 11 4 2022 6 7 2427 2433 2473-9529 10.1182/bloodadvances.2021005616 10.1182/bloodadvances.2021005616 34749396 PMC8575532

Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Transplantation and Cellular Therapy Infante Maria-Stefania Nemirovsky David Devlin Sean DeWolf Susan Tamari Roni Dahi Parastoo B. Lee Yeon Joo Chung David J. Politikos Ioannis Barker Juliet Giralt Sergio A. Babady N. Esther Ramanathan Lakshmi Papanicolaou Genovefa A. Seo Susan Kamboj Mini Perales Miguel-Angel Shah Gunjan L. Elsevier BV 1 2024 30 1 116.e1 116.e12 2666-6367 10.1016/j.jtct.2023.09.027 10.1016/j.jtct.2023.09.027 PMC11220618 37806446

Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence Infection Lin Hui Xian Jaime Cho Sanda Meyyur Aravamudan Veeraraghavan Sanda Hnin Yu Palraj Raj Molton James S. Venkatachalam Indumathi Springer Science and Business Media LLC 2 1 2021 49 3 401 410 0300-8126 10.1007/s15010-020-01557-7 10.1007/s15010-020-01557-7 33389708 PMC7778417

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients Clin Infect Dis Najjar-Debbiny Ronza Gronich Naomi Weber Gabriel Khoury Johad Amar Maisam Stein Nili Goldstein Lee Hilary Saliba Walid Oxford University Press (OUP) 2023 76 3 e342 e349 1058-4838 10.1093/cid/ciac443 10.1093/cid/ciac443 35653428 PMC9214014

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN) Leukemia Terpos Evangelos Musto Pellegrino Engelhardt Monika Delforge Michel Cook Gordon Gay Francesca van de Donk Niels W. C. J. Ntanasis-Stathopoulos Ioannis Vangsted Annette Juul Driessen Christoph Schjesvold Fredrik Cerchione Claudio Zweegman Sonja Hajek Roman Moreau Philippe Einsele Hermann San-Miguel Jesus Boccadoro Mario Dimopoulos Meletios A. Sonneveld Pieter Ludwig Heinz Springer Science and Business Media LLC 4 5 2023 37 6 1175 1185 0887-6924 10.1038/s41375-023-01920-1 10.1038/s41375-023-01920-1 37142661 PMC10157596

Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy – a case report BMC Infectious Diseases Rejeski Kai Kunz Wolfgang G. Rudelius Martina Bücklein Veit Blumenberg Viktoria Schmidt Christian Karschnia Philipp Schöberl Florian Dimitriadis Konstantin von Baumgarten Louisa Stemmler Joachim Weigert Oliver Dreyling Martin von Bergwelt-Baildon Michael Subklewe Marion Springer Science and Business Media LLC 28 1 2021 21 1 121 1471-2334 10.1186/s12879-020-05755-4 10.1186/s12879-020-05755-4 33509115 PMC7841988

Invasive Mold Infections After Chimeric Antigen Receptor–Modified T-Cell Therapy: A Case Series, Review of the Literature, and Implications for Prophylaxis Clinical Infectious Diseases Haidar Ghady Dorritie Kathleen Farah Rafic Bogdanovich Tatiana Nguyen M Hong Samanta Palash Oxford University Press (OUP) 22 11 2019 71 3 672 676 1058-4838 10.1093/cid/ciz1127 10.1093/cid/ciz1127 31756246

The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes Blood Advances Faruqi Aiman J. Ligon John A. Borgman Paul Steinberg Seth M. Foley Toni Little Lauren Mackall Crystal L. Lee Daniel W. Fry Terry J. Shalabi Haneen Brudno Jennifer Yates Bonnie Mikkilineni Lekha Kochenderfer James Shah Nirali N. American Society of Hematology 1 12 2022 6 23 6040 6050 2473-9529 10.1182/bloodadvances.2022007676 10.1182/bloodadvances.2022007676 35939781 PMC9700270

Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States Transplantation and Cellular Therapy Jacobson Caron A. Locke Frederick L. Ma Long Asubonteng Julius Hu Zhen-Huan Siddiqi Tanya Ahmed Sairah Ghobadi Armin Miklos David Bernard Lin Yi Perales Miguel-Angel Lunning Matthew Alexander Herr Megan M. Hill Brian T. Ganguly Siddhartha Dong Hua Nikiforow Sarah Hooper Michele Kawashima Jun Xu Hairong Pasquini Marcelo C. Elsevier BV 9 2022 28 9 581.e1 581.e8 2666-6367 10.1016/j.jtct.2022.05.026 10.1016/j.jtct.2022.05.026 35609867 PMC9427701

Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells Leukemia & Lymphoma Wittmann Dayagi Talya Sherman Gilad Bielorai Bella Adam Etai Besser Michal J. Shimoni Avichai Nagler Arnon Toren Amos Jacoby Elad Avigdor Abraham Informa UK Limited 10 2 2021 62 7 1692 1701 1042-8194 10.1080/10428194.2021.1881506 10.1080/10428194.2021.1881506 33563059

The role of senescent cells in ageing Nature van Deursen Jan M. Springer Science and Business Media LLC 21 5 2014 509 7501 439 446 0028-0836 10.1038/nature13193 10.1038/nature13193 24848057 PMC4214092

Infectious Complications Associated with CAR T-Cell Therapy Blood Mikkilineni Lekha Shahani Shilpa Yates Bonnie Steinberg Seth M. Palmore Tara Nussenblatt Veronique Lee Daniel W. Kaplan Rosandra N. Mackall Crystal L. Fry Terry J. Gea-Banacloche Juan Jerussi Theresa Kochenderfer James N. Shah Nirali N. American Society of Hematology 13 11 2019 134 Supplement_1 4449 4449 0006-4971 10.1182/blood-2019-131170 10.1182/blood-2019-131170

Bendamustine Is a Safe and Effective Regimen for Lymphodepletion before Tisagenlecleucel in Patients with Large B-Cell Lymphomas Blood Ghilardi Guido Chong Elise A Svoboda Jakub Wohlfarth Philipp Dwivedy Nasta Sunita Williamson Staci Landsburg Daniel J Gerson James N Barta Stefan K. Pajarillo Raymone Myers Jessie Yelton Rebecca Ballard Hatcher J. Gier Shannon H Victoriano Danielle Weber Elizabeth Napier Ellen Lacey Simon F Garfall Alfred L. Porter David L Jaeger Ulrich Maziarz Richard T. Ruella Marco Schuster Stephen J American Society of Hematology 5 11 2021 138 Supplement 1 1438 0006-4971 10.1182/blood-2021-151766 10.1182/blood-2021-151766 PMC11332249 35690221

Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL. Journal of Clinical Oncology Shah Bijal D. Jacobson Caron A. Solomon Scott Jain Nitin Vainorius Monika Heery Christopher Ryan He Fiona C. Reshef Ran Herrera Alex Francisco Akard Luke Paul Sauter Craig Steven American Society of Clinical Oncology (ASCO) 20 5 2021 39 15_suppl 7516 7516 0732-183X 10.1200/jco.2021.39.15_suppl.7516 10.1200/jco.2021.39.15_suppl.7516

Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study Journal for ImmunoTherapy of Cancer Walti Carla S Loes Andrea N Shuey Kiel Krantz Elizabeth M Boonyaratanakornkit Jim Keane-Candib Jacob Loeffelholz Tillie Wolf Caitlin R Taylor Justin J Gardner Rebecca A Green Damian J Cowan Andrew J Maloney David G Turtle Cameron J Pergam Steven A Chu Helen Y Bloom Jesse D Hill Joshua A BMJ 10 2021 9 10 e003428 2051-1426 10.1136/jitc-2021-003428 10.1136/jitc-2021-003428 34702753 PMC8549667

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) Annals of Oncology Hayden P.J. Roddie C. Bader P. Basak G.W. Bonig H. Bonini C. Chabannon C. Ciceri F. Corbacioglu S. Ellard R. Sanchez-Guijo F. Jäger U. Hildebrandt M. Hudecek M. Kersten M.J. Köhl U. Kuball J. Mielke S. Mohty M. Murray J. Nagler A. Rees J. Rioufol C. Saccardi R. Snowden J.A. Styczynski J. Subklewe M. Thieblemont C. Topp M. Ispizua Á.U. Chen D. Vrhovac R. Gribben J.G. Kröger N. Einsele H. Yakoub-Agha I. Elsevier BV 3 2022 33 3 259 275 0923-7534 10.1016/j.annonc.2021.12.003 10.1016/j.annonc.2021.12.003 34923107

Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies Transplant Infectious Disease Kampouri Eleftheria Little Jessica S. Rejeski Kai Manuel Oriol Hammond Sarah P. Hill Joshua A. Wiley 3 10 2023 25 S1 e14157 1398-2273 10.1111/tid.14157 10.1111/tid.14157 37787373

Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper Infection Los-Arcos Ibai Iacoboni Gloria Aguilar-Guisado Manuela Alsina-Manrique Laia Díaz de Heredia Cristina Fortuny-Guasch Claudia García-Cadenas Irene García-Vidal Carolina González-Vicent Marta Hernani Rafael Kwon Mi Machado Marina Martínez-Gómez Xavier Maldonado Valentín Ortiz Pla Carolina Pinto Piñana José Luis Pomar Virginia Reguera-Ortega Juan Luis Salavert Miguel Soler-Palacín Pere Vázquez-López Lourdes Barba Pere Ruiz-Camps Isabel Springer Science and Business Media LLC 2021 49 2 215 231 0300-8126 10.1007/s15010-020-01521-5 10.1007/s15010-020-01521-5 32979154 PMC7518951

How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies Blood Hill Joshua A. Seo Susan K. American Society of Hematology 20 8 2020 136 8 925 935 0006-4971 10.1182/blood.2019004000 10.1182/blood.2019004000 32582924 PMC7441168

Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022) Transplantation and Cellular Therapy Dioverti Veronica Boghdadly Zeinab El Shahid Zainab Waghmare Alpana Abidi Maheen Z. Pergam Steven Boeckh Michael Dadwal Sanjeet Kamboj Mini Seo Susan Chemaly Roy F. Papanicolaou Genovefa A. Elsevier BV 12 2022 28 12 810 821 2666-6367 10.1016/j.jtct.2022.09.002 10.1016/j.jtct.2022.09.002 36103987 PMC9464362

Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update Journal of Clinical Oncology Taplitz Randy A. Kennedy Erin B. Bow Eric J. Crews Jennie Gleason Charise Hawley Douglas K. Langston Amelia A. Nastoupil Loretta J. Rajotte Michelle Rolston Kenneth V. Strasfeld Lynne Flowers Christopher R. American Society of Clinical Oncology (ASCO) 20 10 2018 36 30 3043 3054 0732-183X 10.1200/jco.18.00374 10.1200/jco.18.00374 30179565

Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma Blood Adv Baird John H. Epstein David J. Tamaresis John S. Ehlinger Zachary Spiegel Jay Y. Craig Juliana Claire Gursharan K. Frank Matthew J. Muffly Lori Shiraz Parveen Meyer Everett Arai Sally Brown Janice (Wes) Johnston Laura Lowsky Robert Negrin Robert S. Rezvani Andrew R. Weng Wen-Kai Latchford Theresa Sahaf Bita Mackall Crystal L. Miklos David B. Sidana Surbhi American Society of Hematology 6 1 2021 5 1 143 155 2473-9529 10.1182/bloodadvances.2020002732 10.1182/bloodadvances.2020002732 33570626 PMC7805341

Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial The Lancet Respiratory Medicine Holland Thomas L. Ginde Adit A. Paredes Roger Murray Thomas A. Engen Nicole Grandits Greg Vekstein Andrew Ivey Noel Mourad Ahmad Sandkovsky Uriel Gottlieb Robert L. Berhe Mezgebe Jain Mamta K. Marines-Price Rubria Agbor Agbor Barbine Tchamba Mateu Lourdes España-Cueto Sergio Lladós Gemma Mylonakis Eleftherios Rogers Ralph Shehadeh Fadi Filbin Michael R. Hibbert Kathryn A. Kim Kami Tran Thanh Morris Peter E. Cassity Evan P. Trautner Barbara Pandit Lavannya M. Knowlton Kirk U. Leither Lindsay Matthay Michael A. Rogers Angela J. Drake Wonder Jones Beatrice Poulakou Garyfallia Syrigos Konstantinos N. Fernández-Cruz Eduardo Di Natale Marisa Almasri Eyad Balerdi-Sarasola Leire Bhagani Sanjay R. Boyle Katherine L. Casey Jonathan D. Chen Peter Douin David J. Files D. Clark Günthard Huldrych F. Hite R. Duncan Hyzy Robert C. Khan Akram Kibirige Moses Kidega Robert Kimuli Ivan Kiweewa Francis Jensen Jens-Ulrik Leshnower Bradley G. Lutaakome Joseph K. Manian Prasad Menon Vidya Morales-Rull Jose Luis O'Mahony D. Shane Overcash J. Scott Ramachandruni Srikant Steingrub Jay S. Taha Hassan S. Waters Michael Young Barnaby E. Phillips Andrew N. Murray Daniel D. Jensen Tomas O. Padilla Maria L. Sahner David Shaw-Saliba Katy Dewar Robin L. Teitelbaum Marc Natarajan Ven Rehman M. Tauseef Pett Sarah Hudson Fleur Touloumi Giota Brown Samuel M. Self Wesley H. Chang Christina C. Sánchez Adriana Weintrob Amy C. Hatlen Timothy Grund Birgit Sharma Shweta Reilly Cavan S. Garbes Pedro Esser Mark T. Templeton Alison Babiker Abdel G. Davey Victoria J. Gelijns Annetine C. Higgs Elizabeth S. Kan Virginia Matthews Gail Thompson B. Taylor Neaton James D. Lane H. Clifford Lundgren Jens D. Elsevier BV 10 2022 10 10 972 984 2213-2600 10.1016/s2213-2600(22)00215-6 10.1016/s2213-2600(22)00215-6 35817072 PMC9270059

Coronavirus (COVID-19) Update: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals Administration USFaD. 2021

Vaccine schedule recommendations and updates for patients with hematologic malignancy post-hematopoietic cell transplant or CAR T-cell therapy Transplant Infectious Disease Reynolds Gemma Hall Victoria G. Teh Benjamin W. Wiley 29 7 2023 25 S1 e14109 1398-2273 10.1111/tid.14109 10.1111/tid.14109 37515788 PMC10909447

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA) Annals of Oncology Hayden P.J. Roddie C. Bader P. Basak G.W. Bonig H. Bonini C. Chabannon C. Ciceri F. Corbacioglu S. Ellard R. Sanchez-Guijo F. Jäger U. Hildebrandt M. Hudecek M. Kersten M.J. Köhl U. Kuball J. Mielke S. Mohty M. Murray J. Nagler A. Rees J. Rioufol C. Saccardi R. Snowden J.A. Styczynski J. Subklewe M. Thieblemont C. Topp M. Ispizua Á.U. Chen D. Vrhovac R. Gribben J.G. Kröger N. Einsele H. Yakoub-Agha I. Elsevier BV 3 2022 33 3 259 275 0923-7534 10.1016/j.annonc.2021.12.003 10.1016/j.annonc.2021.12.003 34923107

SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study EClinicalMedicine Hill Joshua A. Martens Michael J. Young Jo-Anne H. Bhavsar Kavita Kou Jianqun Chen Min Lee Lik Wee Baluch Aliyah Dhodapkar Madhav V. Nakamura Ryotaro Peyton Kristin Shahid Zainab Armistead Paul Westervelt Peter McCarty John McGuirk Joseph Hamadani Mehdi DeWolf Susan Hosszu Kinga Sharon Elad Spahn Ashley Toor Amir A. Waldvogel Stephanie Greenberger Lee M. Auletta Jeffery J. Horowitz Mary M. Riches Marcie L. Perales Miguel-Angel Elsevier BV 5 2023 59 101983 2589-5370 10.1016/j.eclinm.2023.101983 10.1016/j.eclinm.2023.101983 37128256 PMC10133891

Respiratory Syncytial Virus (RSV) Vaccine VIS Prevention CfDCa. 2023 https://www.cdc.gov/vaccines/hcp/vis/vis-statements/rsv.html

HFCI. Immunotherapy (IMTX): Vaccination after B cell-targeted CAR-T cell therapy for Adult and Pediatric Immune Effector Cell (IEC) Patients LTFU https://www.fredhutch.org/content/dam/www/research/patient-treatment-and-support/ltfu/imtx_immunotherapy_vaccination_b_cell_targeted.pdf

How I treat cytopenias after CAR T-cell therapy Blood Jain Tania Olson Timothy S Locke Frederick L. American Society of Hematology 17 2 2023 141 20 2460 2469 0006-4971 10.1182/blood.2022017415 10.1182/blood.2022017415 36800563 PMC10646792

Eltrombopag Stimulation for Neutrophil and Platelet Recovery Following Axicabtagene Ciloleucel (axi-cel) Therapy in Lymphoma Blood Wesson William Nelson Maggie Mushtaq Muhammad Bansal Rajat Kribs Robert Singh Anurag K. Hoffmann Marc Tun Aung M Abdallah Al-Ola Abdelhakim Haitham Abhyankar Sunil H McGuirk Joseph P. Shune Leyla O. Ahmed Nausheen American Society of Hematology 15 11 2022 140 Supplement 1 12757 12759 0006-4971 10.1182/blood-2022-162433 10.1182/blood-2022-162433

Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy Transplantation and Cellular Therapy Davis James A. Sborov Douglas W. Wesson William Julian Kelley Abdallah Al-Ola McGuirk Joseph P. Ahmed Nausheen Hashmi Hamza Elsevier BV 9 2023 29 9 567 571 2666-6367 10.1016/j.jtct.2023.05.012 10.1016/j.jtct.2023.05.012 37225044

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) Haematologica Yakoub-Agha Ibrahim Chabannon Christian Bader Peter Basak Grzegorz W. Bonig Halvard Ciceri Fabio Corbacioglu Selim Duarte Rafael F. Einsele Hermann Hudecek Michael Kersten Marie José Köhl Ulrike Kuball Jürgen Mielke Stephan Mohty Mohamad Murray John Nagler Arnon Robinson Stephen Saccardi Riccardo Sanchez-Guijo Fermin Snowden John A. Srour Micha Styczynski Jan Urbano-Ispizua Alvaro Hayden Patrick J. Kröger Nicolaus Ferrata Storti Foundation (Haematologica) 2020 105 2 297 316 0390-6078 10.3324/haematol.2019.229781 10.3324/haematol.2019.229781 31753925 PMC7012497

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations Blood Rejeski Kai Subklewe Marion Aljurf Mahmoud Bachy Emmanuel Balduzzi Adriana Barba Pere Bruno Benedetto Benjamin Reuben Carrabba Matteo G. Chabannon Christian Ciceri Fabio Corradini Paolo Delgado Julio Di Blasi Roberta Greco Raffaella Houot Roch Iacoboni Gloria Jäger Ulrich Kersten Marie José Mielke Stephan Nagler Arnon Onida Francesco Peric Zinaida Roddie Claire Ruggeri Annalisa Sánchez-Guijo Fermín Sánchez-Ortega Isabel Schneidawind Dominik Schubert Maria-Luisa Snowden John A. Thieblemont Catherine Topp Max Zinzani Pier Luigi Gribben John G. Bonini Chiara Sureda Anna Yakoub-Agha Ibrahim American Society of Hematology 7 9 2023 142 10 865 877 0006-4971 10.1182/blood.2023020578 10.1182/blood.2023020578 37300386

Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ Blood Alvarado Luigi J. Huntsman Heather D. Cheng Hai Townsley Danielle M. Winkler Thomas Feng Xingmin Dunbar Cynthia E. Young Neal S. Larochelle Andre American Society of Hematology 9 5 2019 133 19 2043 2055 0006-4971 10.1182/blood-2018-11-884486 10.1182/blood-2018-11-884486 30803992 PMC6509545

Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians Expert Review of Hematology Kampouri Eleftheria Walti Carla S. Gauthier Jordan Hill Joshua A. Informa UK Limited 3 4 2022 15 4 305 320 1747-4086 10.1080/17474086.2022.2063833 10.1080/17474086.2022.2063833 35385358